Articles Vol. 63 No. 6 (2022) 09/11/2022

ASSESSMENT OF QUANTITATIVE POINT-OF-CARE G6PD ACTIVITY BY USING CARESTART BIOSENSOR IN MALARIA ENDEMIC ZONE OF TUY DUC DISTTRICT, DAK NONG PROVINCE

Nguyen Duc Giang1,2, Vu Sinh Nam3,4, Huynh Hong Quang5,6, Chau Van Khanh5,6, Ho Van Hoang5,6
1 National Institute of Malariology, Parasitology, and Entomology
2 Viện Sốt rét-Ký sinh trùng-Côn trùng Trung ương
3 National Institute of Hygiene and Epidemiology
4 Viện Vệ sinh Dịch tễ Trung ương
5 Institute of Malariology, Parasitology, and Entomology Quy Nhon
6 Viện Sốt rét-Ký sinh trùng-Côn trùng Quy Nhơn
Corresponding author: giangnimpe@gmail.com
DOI: 10.52163/yhc.v63i6.473
12 Views
0 Downloads
Keywords
G6PD deficiency, Plasmodium vivax, CareStart™ G6PD biosensor.
Abstract

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymopathy in the
human population, especially those living in malaria endemic areas. Decreased G6PD enzymatic
activity is associated with 8-aminoquinolines-induced hemolysis leading to severe complication, and
malaria elimination challenge, especially in Plasmodium vivax malaria. This study was conducted to
the enzyme G6PD activity deficiency in population are living in malaria endemic zone in Tuy Duc
district, Dak Nong province. Method: In order to inform the safer use of 8-aminoquinolines, a crosssectional study which included 2,809 subjects was conducted using a quantitative CareStart™ G6PD
biosensor (AccessBio, USA). Results: The results showed that the normal value of G6PD activity
is 9.03 IU/g Hb, the adjusted male median is 8.78 IU/g Hb, the 30% and 80% cut-off values were
2.63 IU/g Hb and 7.02 IU/g Hb, respectively. The overall prevalence of G6PD deficiency of study
population was 2,31%, with the figures for male and female were 3.65% and 1.49%, respectively. The
prevalence of G6PD deficiency was significantly different among ethnic minority groups (p<0.005).
Conclusions: The quantitative test should include point-of-care G6PD activity testing in clinical
practice of vivax malaria to allow the safe use of 8-aminoquinolines for radical treatment.

References
[1]
Tạ Thị Tĩnh, Lê Minh Đạo, Nguyễn Minh Google Scholar
[2]
Hùng, Trần Thị Uyên, Thiếu enzyme glucose-6- Google Scholar
[3]
phosphate dehydrogenase trong một số nhóm dân Google Scholar
[4]
tộc khác nhau tại Việt Nam. Hội nghị Quốc gia về Google Scholar
[5]
Sốt rét, Ký sinh trùng và Côn trùng (2001-2005), Google Scholar
[6]
Nhà xuất bản Y học, 2006. Google Scholar
[7]
Bancone G, Menard D, Khim N et al., Molecular Google Scholar
[8]
characterization and mapping of glucose-6- Google Scholar
[9]
phosphate dehydrogenase (G6PD) mutations Google Scholar
[10]
in the Greater Mekong Subregion. Malaria Google Scholar
[11]
journal, 18(1), 2009. Google Scholar
[12]
Chu CS, Freedman DO, Tafenoquine and Google Scholar
[13]
G6PD: A primer for clinicians. Journal of travel Google Scholar
[14]
medicine, 26(4), taz023, 2019. Google Scholar
[15]
Domingo GJ, Satyagraha AW, Anvikar A et Google Scholar
[16]
al., G6PD testing in support of treatment and Google Scholar
[17]
elimination of malaria: Recommendations Google Scholar
[18]
for evaluation of G6PD tests, Malaria Google Scholar
[19]
Journal, 12:391, 2013. Google Scholar
[20]
Oo NN, Bancone G, Maw LZ et al., Validation Google Scholar
[21]
of G6PD point-of-care tests among healthy Google Scholar
[22]
volunteers in Yangon, Myanmar. PloS Google Scholar
[23]
one, 11(4):e0152304, 2016. Google Scholar
[24]
Pfeffer DA, Ley B, Howes RE et al., Quantification Google Scholar
[25]
of glucose-6-phosphate dehydrogenase activity Google Scholar
[26]
by spectrophotometry: A systematic review and Google Scholar
[27]
meta-analysis. PLoS Med 17(5): e1003084, 2020. Google Scholar
[28]
Rueangweerayut R, Bancone G, Harrell EJ et Google Scholar
[29]
al., Hemolytic potential of tafenoquine in female Google Scholar
[30]
volunteers heterozygous for G6PD deficiency Google Scholar
[31]
(G6PD Mahidol variant) versus G6PD-normal Google Scholar
[32]
volunteers. The American Journal of Tropical Google Scholar
[33]
Medicine and Hygiene, 97(3):702-711, 2017. Google Scholar
[34]
WHO, Point-of-care G6PD testing to support Google Scholar
[35]
safe use of primaquine for the treatment of vivax Google Scholar
[36]
malaria. WHO Evidence review group meeting Google Scholar
[37]
report, WHO/UNAIDSbuilding, 2015. Google Scholar
[38]
WHO, Guide to G6PD deficiency rapid diagnostic Google Scholar
[39]
testing to support P. vivax radical cure, 2018. Google Scholar
[40]
WHO, World Malaria Report 2020, 2020. Google Scholar